Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study

Arch Pathol Lab Med. 2004 May;128(5):519-26. doi: 10.5858/2004-128-519-COPCPW.

Abstract

Context: Plasma anti-Xa and anti-IIa activities correlate with the dose of low-molecular-weight heparin, and D-dimer and thrombin-antithrombin complexes are markers of procoagulant activity.

Objective: To investigate the relationship between plasma coagulation parameters and patient characteristics, including renal function, thromboprophylaxis, and incidence of venous thromboembolism (VTE) in the MEDENOX study population.

Design: Controlled, multicenter, double-blind, randomized study.

Patients: Two hundred twenty-four acutely ill medical patients.

Interventions: Either 20 or 40 mg of enoxaparin administered subcutaneously or a placebo once daily for 10 (+/-4) days.

Main outcome measures: VTE and plasma anti-Xa and anti-IIa activities, D-dimer, and thrombin-antithrombin levels in blood collected before prophylaxis was given (day 0) and after the last injection of the study drug.

Results and conclusions: Anti-Xa activity correlated with the dose of enoxaparin. In patients with mild or moderate renal impairment, there was no significant relationship between anti-Xa activity and the creatinine clearance rate. D-dimer concentrations were lower at day 10 (+/-4) in the 40-mg group, which had a 63% lower VTE incidence, than at day 0. No venographically confirmed thromboses were found in patients with a normal D-dimer concentration (<0.5 microg/mL [0.5 mg/L]). D-dimer levels were higher in patients with VTE than in those without VTE, but no predictive value could be demonstrated for individual patients.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Coagulation Factors / analysis*
  • Double-Blind Method
  • Enoxaparin / therapeutic use*
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Male
  • Pulmonary Embolism / prevention & control*
  • Thromboembolism / diagnosis
  • Thromboembolism / epidemiology
  • Thromboembolism / prevention & control
  • Treatment Outcome
  • Venous Thrombosis / prevention & control*

Substances

  • Blood Coagulation Factors
  • Enoxaparin
  • Fibrinolytic Agents